The rat has been a staple in drug research for decades. With well characterized immune systems that are more closely predictive of human conditions, rats make excellent lab testing subjects. But Open Monoclonal Technologies Inc. (OMT), a 2007 start-up based in Palo Alto, Calif., is elevating the rat's role in drug development with a fully human monoclonal antibody platform based on transgenic rats.